As a result, cancer therapies that target EGFR, using drugs that directly bind to the receptor, have been extensively used in clinical treatments for EGFR-positive NSCLC, and their strong efficacy has been well-established (Herbst et al., 2018; Pan et al., 2023). This evidence concerns the gene EGFR and non-small cell lung carcinoma.